Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the

Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

Wash. (March 23, 2022) - Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31,

2021, and provides updates on its antiviral pipeline, upcoming milestones and business activities.

is an eventful time at Cocrystal as we thoughtfully advance our antiviral programs for the treatment of influenza and COVID-19,"

said Sam Lee, Ph.D., co-interim CEO and President of Cocrystal. "Enrollment is underway in our Phase 1 trial in Australia with

our antiviral compound CC-42344 for pandemic and seasonal influenza A, keeping us on track for data readout later this year.

affirm plans to initiate first-in-human clinical studies as soon as possible in 2022 with two SARS-CoV-2 protease inhibitors, including

our inhalation/pulmonary compound CDI-45205 and an orally administered compound," Dr. Lee added. "Early this year,

we received extensive comments from the U.S. Food and Drug Administration (FDA) on our pre-IND briefing package for CDI-45205 that

provide valuable information in designing Phase 1 and Phase 2 studies for both CDI-45205 and our orally administered program."

continue advancing multiple high-value antiviral compounds into clinical development and remain opportunistic," said James Martin,

co-interim CEO and CFO. "Importantly, given current markets and world economic stability conditions, we continue to be well positioned

to execute on our strategy with a clean capital structure and a cash balance we believe is sufficient to fund planned operations through

antiviral drugs are effective only against certain strains of a virus and are less effective or not effective at all against other strains.

Cocrystal is developing drug candidates that specifically target proteins involved in viral replication. Despite the various strains

of virus that may exist or emerge, these enzymes are required for viral replication and are essentially similar (highly conserved) among

all strains. By targeting these highly conserved regions of the replication enzymes, our antiviral compounds are designed and tested

to be effective against major virus strains.

and Other Coronavirus Programs

targeting viral replication enzymes and protease, we believe it is possible to develop an effective treatment for all coronavirus diseases

including COVID-19, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Our main SARS-CoV-2 protease

inhibitors showed potent in vitro pan-viral activity against common human coronaviruses, rhinoviruses and respiratory enteroviruses

that frequently cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis.

global market for influenza therapeutics is expected to reach nearly $6.5 billion by 2022, according to a report published by BCC Research

2020 Cocrystal reported revenues under an influenza A/B collaboration with Merck consisting of research and development (R&D) services

performed by Cocrystal and reimbursed by Merck. As discussed above, in January 2021 Merck assumed all activities and expenses associated

with the continued development of the influenza A/B compounds discovered under this collaboration. As anticipated, Cocrystal reported

no revenues for 2021 compared with $2.0 million in revenues for 2020. Under the terms of the Merck collaboration, Cocrystal is eligible

to receive up to $156 million in payments related to designated developments, regulatory and sales milestones, as well as royalties on

expenses for 2021 were $8.8 million compared with $6.0 million for 2020, with the increase primarily related to COVID-19 and influenza

programs. The Company expects R&D expenses to increase during 2022 due to the advancement of our influenza A program into the clinic

and progress with preclinical COVID-19 programs toward clinical development. General and administrative expenses for 2021 were $5.4 million

compared with $5.6 million for 2020, with the decrease primarily due to reduced professional fees resulting from the conclusion of certain

previously reported legal matters.

net loss for 2021 was $14.2 million, or $0.16 per share, compared with a net loss for 2020 of $9.6 million, or $0.17 per share.

Company reported unrestricted cash of $58.7 million as of December 31, 2021, compared with $33.0 million as of December 31, 2020. Net

cash used in operating activities for 2021 was $12.7 million. During 2021 the company raised $38.5 million, net of transaction costs,

which included net proceeds of approximately $2.1 million from the sale of common stock through an At-The-Market (ATM) facility in January

2021 and $36.4 million in net proceeds from a public offering of common stock May 2021. The Company reported working capital of $57.8

million as of December 31, 2021.

Cocrystal Pharma, Inc.

Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication

process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based

technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal,

please visit www.cocrystalpharma.com.

Note Regarding Forward-Looking Statements

press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including

statements regarding our goals of initiating two Phase 1 studies for our COVID-19 programs in 2022, our expectations of reporting data

from the Phase 1 clinical study of our Influenza A product candidate later in 2022, the viability and efficacy of potential treatments

for coronavirus and other diseases, expectations for the global market for influenza therapeutics, our attempts to discover replication

inhibitors, our development of antiviral treatments for norovirus, our expectations concerning R&D expenses, the expected sufficiency

of our cash balance to fund our planned operations through 2023 and our liquidity. The words "believe," "may,"

"estimate," "continue," "anticipate," "intend," "should," "plan,"

"could," "target," "potential," "is likely," "will," "expect"

and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking

statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking

statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include,

but are not limited to, the risks arising from the impact of the COVID-19 pandemic and/or the Ukraine war on our Company, our collaboration

partners, and on the national and global economy, including manufacturing and research delays arising from raw materials and labor shortages,

supply chain disruptions and other business interruptions including and adverse impacts on our ability to obtain raw materials and test

animals as well as similar problems with our vendors and our current Clinical Research Organization (CRO) and any future CROs and Contract

Manufacturing Organizations (CMOs), the ability of our current CRO to recruit volunteers for, and to proceed with, clinical trials, possible

delays resulting from future lockdowns in Australia, our reliance on Merck for further development in the influenza A/B program under

the license and collaboration agreement, our collaboration partners' technology and software performing as expected, the results

of future preclinical and clinical trials, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes,

development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government,

potential mutations in a virus we are targeting which may result in variants that are resistant to a product candidate we develop, and

any additional costs related to unfavorable future outcome of pending litigation or any unanticipated claims. Further information on

our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021.

Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our

actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation

to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as

may be required by law.

STATEMENTS OF OPERATIONS

thousands, except per share data)